Welcome to our dedicated page for Lifemd SEC filings (Ticker: LFMDP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LifeMD, Inc. 8.875% Series A Cumulative Perpetual Preferred Stock (Nasdaq: LFMDP) provides access to regulatory documents filed by LifeMD, Inc., the issuer of this preferred security. These filings, drawn from the SEC’s EDGAR system, include current reports on Form 8‑K and other disclosures that reference both the company’s common stock and its 8.875% Series A Cumulative Perpetual Preferred Stock.
LifeMD’s Form 8‑K filings illustrate how SEC reports can inform investors in LFMDP. For example, the company has filed 8‑Ks describing changes in its independent registered public accounting firms, including the dismissal of prior auditors, the identification of material weaknesses in internal control over financial reporting, and the appointment of PricewaterhouseCoopers LLP. Other 8‑Ks discuss the release of financial results for specific periods and the furnishing of related press releases as exhibits.
These filings also show how LifeMD reports broader corporate events that may be relevant to preferred stockholders. The company has disclosed the divestiture of its majority interest in WorkSimpli Software LLC, positioning LifeMD as a pure‑play virtual care and pharmacy platform, and has described its focus on expanding virtual care and pharmacy offerings. In addition, press releases incorporated into filings and separate company announcements detail quarterly cash dividends authorized on the 8.875% Series A Cumulative Perpetual Preferred Stock, directly affecting LFMDP holders.
Through this page, users can review LifeMD’s filed balance sheets, statements of operations, and related notes where the Series A Preferred Stock is presented within the capital structure, including information about authorized and outstanding shares. Current reports also reference the preferred stock explicitly in the context of material events and exhibit listings.
Stock Titan enhances this raw filing data with AI‑powered summaries that explain the key points of complex documents in plain language. As new LifeMD filings are posted to EDGAR, they are updated on this page, allowing investors to quickly see how changes in auditors, internal controls, financial reporting, corporate transactions, or dividend decisions might relate to LFMDP. Users can also review filings that touch on executive appointments, compensation arrangements, and other governance topics that shape the environment in which the preferred stock exists.
Form 144 notice for proposed sale of securities. The filer intends to sell 75,000 common shares of the issuer through Charles Schwab (3000 Schwab Way, Westlake, TX) on 09/10/2025 on NASDAQ, with an aggregate market value of $459,000. The issuer has 47,417,393 shares outstanding. The 75,000 shares were acquired by RSU vesting from the issuer on 03/01/2025. No securities were sold by the selling person during the past three months. The notice includes the seller's representation that they possess no undisclosed material adverse information.
LifeMD insider stock award vested: The company's Chief Legal Officer and General Counsel, Eric H. Yecies, had a grant of 50,000 common shares vest on 08/22/2025. The report shows those shares were issued at a $0 per-share price as a performance-based award that vested.
Following this vested award the reporting person beneficially owns 388,900 shares of the issuer's common stock. The Form 4 discloses this as a non-derivative acquisition reflecting the conversion of a performance stock grant into common shares.
LifeMD, Inc. (LFMD) reporting person Dennis Wijnker, identified as an officer with the title Chief Technology Officer, reported a change in beneficial ownership on 08/22/2025. The Form 4 shows a grant of 25,000 shares of common stock that vested on that date with an acquisition price recorded as $0, described as performance stock. After the vesting, the reporting person beneficially owned 175,000 shares. The form is signed and dated 08/26/2025. The filing indicates this was a routine vesting event rather than an open-market purchase or sale.
Maria E. Stan, Chief Accounting Officer of LifeMD, Inc. (LFMD), reported a non‑derivative acquisition of common stock that vested on August 22, 2025. The Form 4 shows a grant of 20,000 shares was recorded as acquired at a price of $0 and the reporting person now beneficially owns 227,500 shares. The filing is signed and dated August 26, 2025. No other transactions or derivative positions are reported.
Insider filing shows grant vesting and holdings Stefan Galluppi, Chief Innovation Officer of LifeMD, Inc. (LFMD), reported an acquisition on 08/22/2025 of 30,000 shares of common stock resulting from a performance stock grant that vested on that date. The reported price is $0, indicating these were shares issued on vesting rather than purchased. After the transaction, Galluppi directly beneficially owns 110,449 shares and indirectly beneficially owns 1,644,800 shares through American Nutra Tech, LLC. The Form 4 was signed on 08/26/2025.
LifeMD insider Jessica Friedeman acquired 50,000 shares of common stock upon vesting of performance stock on 08/22/2025. The Form 4 shows the transaction was reported on 08/26/2025 and lists Friedeman's role as Officer — Chief Marketing Officer. The filing reports 220,000 shares of common stock beneficially owned by the reporting person after the transaction. The acquisition is recorded as non‑derivative, with a reported price of $0 reflecting the vesting of previously granted performance stock.
LifeMD, Inc. reporting person Marc David Benathen, the company's Chief Financial Officer, had 87,000 shares of common stock become vested and were reported as acquired on 08/22/2025 at a reported price of $0, described as performance stock that vested. Following the transaction he beneficially owns 426,554 shares. The Form 4 is filed individually by the reporting person and lists the reporting person's address as LifeMD, Inc., 236 Fifth Avenue, Suite 400, New York, NY 10001.
LifeMD insider stock grant vested: Nicholas P. Alvarez, Chief Acquisition Officer of LifeMD, acquired 100,000 common shares on 08/22/2025 as a result of a performance stock grant that vested. The shares were issued at a $0 price, reflecting a vesting award rather than a purchased transaction. Following this vesting, Alvarez beneficially owns 680,000 common shares in total, held directly. The Form 4 was signed on 08/26/2025.
Insider Form 4 summary: Shayna Webb Dray, listed as Chief Operating Officer and a director-level reporting person at LifeMD, Inc., reported an acquisition on 08/22/2025 of 30,000 shares of the issuer's common stock through the vesting of performance stock. The transaction price is reported as $0, and following the vesting Dray beneficially owns 295,000 shares. The Form 4 was signed on 08/26/2025. The filing indicates the shares were granted as performance stock that vested on the transaction date.
LifeMD, Inc. reported another change in its independent auditor and highlighted ongoing internal control weaknesses. On August 15, 2025, with Audit Committee approval, the company dismissed CBIZ CPAs P.C., which had only been appointed in April 2025 and never issued an audit report.
On August 18, 2025, LifeMD appointed PricewaterhouseCoopers LLP (PwC) as its independent registered public accounting firm for the year ending December 31, 2025. The company states it has not previously consulted PwC on accounting or auditing matters. LifeMD also disclosed material weaknesses in internal control over financial reporting related to IT general controls, review of key third-party SOC reports, and business process controls over information produced by the company and evidence of formal review procedures.